XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.
NCT ID: NCT01024699
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2009-11-30
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XLIF
This group will have the XLIF procedure done.
No interventions assigned to this group
MAS TLIF
This group will have the MAS TLIF procedure done.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Patients who present with symptomatic Grade I or II degenerative spondylolisthesis at 1 or 2 contiguous lumbar levels between L1 and L5 and are surgical candidates for interbody lumbar fusion surgery; symptoms should include radiculopathy and/or neurogenic claudication with or without back pain;
\- Patients who have been unresponsive to at least 6 months of conservative treatments or exhibit progressive neurological symptoms in the face of conservative treatment;
\- Patients who understand the conditions of enrollment and are willing to sign an informed consent to participate in the study.
Exclusion Criteria
\- Patients who have had previous lumbar fusion surgery;
\- Patients with lytic spondylolisthesis or a defect of the pars interarticularis;
\- Patients with radiographic confirmation of Grade IV facet joint disease or degeneration;
\- Patients with non-contained or extruded herniated nucleus pulposus
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NuVasive
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Vincent-Jacksonville
Jacksonville, Florida, United States
Celebration Florida Hospital
Kissimmee, Florida, United States
St. Joseph's/Candler Health System
Savannah, Georgia, United States
Northwest Orthopaedic Specialists, P.S.
Paducah, Kentucky, United States
Orthopaedic Clinic-Riverside Campus, University of Minnesota
Minneapolis, Minnesota, United States
Duke University Medical Center
Durham, North Carolina, United States
The Methodist Hospital
Houston, Texas, United States
Spine and Sports Institute
Richland, Washington, United States
Northwest Orthopaedic Specialists, P.S.
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUVA.X0901
Identifier Type: -
Identifier Source: org_study_id